Dr Keren Middelkoop
Affiliations
- Associate Member, Institute of Infectious Disease and Molecular Medicine
- Senior Research Officer, clinical and TB Division leader, Desmond Tutu HIV Centre (DTHC), Desmond Tutu HIV Foundation
- Clinical and Community HIV-Tuberculosis Research Collaborating Centre
Key Expertise
HIV Prevention, Management of HIV & HIV-associated infections, TB, Non-communicable Disease
Main Research Focus
Keren Middelkoop is an experienced clinician scientist with over 20 years of experience in clinical trials, public health and epidemiology studies. Keren has led a series of community-based studies on the local TB epidemic and the impact of highly active anti-retroviral HIV therapy on community TB. She has a solid body of work investigating community TB transmission, including infection prevalence studies, molecular epidemiology studies and proof of concept studies exploring methods for detecting airborne Mtb in congregate setting. She a local PI on a number of TB treatment and TB and HIV prevention trials.
Most Significant Paper Authored in 2025
BCG Revaccination for the Prevention of Sustained Mycobacterium tuberculosis Infection.
Schmidt AC, Fairlie L, Hellstrӧm E, Kany Kany Luabeya A, Middelkoop K, Naidoo K, Nair G, Gela A, Nemes E, Scriba TJ, Cinar A, Frahm N, Mogg R, Kaufman D, Dunne WW, and Hatherill M, and the BCG REVAX Study team. (2025).
This randomized, double-blind, placebo controlled, phase 2b trial assessed the efficacy of BCG revaccination of IGRA-negative adolescents for protection from sustained Mtb infection. While this study also had a negative finding, this was well conducted research despite trying conditions, including the COVID pandemic. While this study cannot address the question regarding the potential role of BCG revaccination in preventing disease among adolescents, it has conclusively shown that BCG revaccination will not prevent sustained TB infection in this age group.